Narissa J. Nonzee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Narissa J. Nonzee has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Beth Ann Glenn
Department of Health Policy and Management, Fielding School of Public Health, UCLA Kaiser Permanente Center for Health Equity, University of California , Los Angeles
2 shared publications - Rita Singhal
Disease Control Bureau, Los Angeles County Department of Public Health, 2615 S Grand Ave #500, Los Angeles, CA 90007, USA
2 shared publications - Roshan Bastani
University of California, Los Angeles (UCLA), Los Angeles, USA
2 shared publications - Andrea Sorensen
Department of Health Policy and Management, Fielding School of Public Health, University of California, Los Angeles, California 90095-1772;
1 shared publication - Ava M. Phisuthikul
Department of Obstetrics and Gynecology, Northwestern University, Chicago, Illinois
1 shared publication - Bettina Pedone
UCLA Arthur Ashe Student Health & Wellness Center, University of California, Los Angeles, 221 Westwood Plaza, Los Angeles, CA 90095, USA
1 shared publication
Latest Publications
- 15 December 2018
- Published by Springer Nature
- Vol. 171, 75-92
The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety
Drug shortages pose a significant public health concern in the United States, and cancer drugs are among those most affected. Shortages present serious safety risks for patients and substantial burden on providers and the healthcare system. Multifaceted drivers of this complex problem include manufacturing disruptions, raw material shortages, regulatory issues, market dynamics, and limited financial incentives that reward quality and production of off-patent drugs. Oncology drugs in short supply have resulted in substitution of less effective or more toxic alternatives, medication errors, and treatment delays, and are especially concerning for medications with no adequate substitute. Consequently, patient outcomes such as disease progression and survival have been adversely affected. Furthermore, emerging gray markets have contributed to cost-prohibitive markups and introduction of counterfeit products that compromise patient safety. The Food and Drug Administration plays a key role in preventing and managing pharmaceutical shortages, largely through regulations requiring early notification of manufacturing interruptions. Other proposed strategies similarly target upstream causes and center on reducing regulatory hurdles for manufacturers and increasing incentives for market entry and quality improvement. Despite progress in preventing supply disruptions, continued exploration of underlying systemic drivers remains critical to informing long-term solutions and alleviating the clinical and economic impact of drug shortages.
- 15 December 2018
- Published by Springer Nature
- Vol. 171, 75-92
The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety
Drug shortages pose a significant public health concern in the United States, and cancer drugs are among those most affected. Shortages present serious safety risks for patients and substantial burden on providers and the healthcare system. Multifaceted drivers of this complex problem include manufacturing disruptions, raw material shortages, regulatory issues, market dynamics, and limited financial incentives that reward quality and production of off-patent drugs. Oncology drugs in short supply have resulted in substitution of less effective or more toxic alternatives, medication errors, and treatment delays, and are especially concerning for medications with no adequate substitute. Consequently, patient outcomes such as disease progression and survival have been adversely affected. Furthermore, emerging gray markets have contributed to cost-prohibitive markups and introduction of counterfeit products that compromise patient safety. The Food and Drug Administration plays a key role in preventing and managing pharmaceutical shortages, largely through regulations requiring early notification of manufacturing interruptions. Other proposed strategies similarly target upstream causes and center on reducing regulatory hurdles for manufacturers and increasing incentives for market entry and quality improvement. Despite progress in preventing supply disruptions, continued exploration of underlying systemic drivers remains critical to informing long-term solutions and alleviating the clinical and economic impact of drug shortages.
- Top Cited PapersOpen Access
- 20 March 2017
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 38 (1) , 489-505
The Affordable Care Act's Impacts on Access to Insurance and Health Care for Low-Income Populations
The Patient Protection and Affordable Care Act (ACA) expands access to health insurance in the United States, and, to date, an estimated 20 million previously uninsured individuals have gained coverage. Understanding the law's impact on coverage, access, utilization, and health outcomes, especially among low-income populations, is critical to informing ongoing debates about its effectiveness and implementation. Early findings indicate that there have been significant reductions in the rate of uninsurance among the poor and among those who live in Medicaid expansion states. In addition, the law has been associated with increased health care access, affordability, and use of preventive and outpatient services among low-income populations, though impacts on inpatient utilization and health outcomes have been less conclusive. Although these early findings are generally consistent with past coverage expansions, continued monitoring of these domains is essential to understand the long-term impact of the law for underserved populations.
- 20 March 2017
- Published by Annual Reviews in Annual Review of Public Health
- Vol. 38 (1) , 489-505
Top Cited PapersOpen AccessThe Affordable Care Act's Impacts on Access to Insurance and Health Care for Low-Income Populations
The Patient Protection and Affordable Care Act (ACA) expands access to health insurance in the United States, and, to date, an estimated 20 million previously uninsured individuals have gained coverage. Understanding the law's impact on coverage, access, utilization, and health outcomes, especially among low-income populations, is critical to informing ongoing debates about its effectiveness and implementation. Early findings indicate that there have been significant reductions in the rate of uninsurance among the poor and among those who live in Medicaid expansion states. In addition, the law has been associated with increased health care access, affordability, and use of preventive and outpatient services among low-income populations, though impacts on inpatient utilization and health outcomes have been less conclusive. Although these early findings are generally consistent with past coverage expansions, continued monitoring of these domains is essential to understand the long-term impact of the law for underserved populations.
- 1 September 2014
- Published by Elsevier in Women's Health Issues
- Vol. 24 (5) , 511-518
What Women Want: Patient Recommendations for Improving Access to Breast and Cervical Cancer Screening and Follow-up
- 1 September 2014
- Published by Elsevier in Women's Health Issues
- Vol. 24 (5) , 511-518
What Women Want: Patient Recommendations for Improving Access to Breast and Cervical Cancer Screening and Follow-up